Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Trial ID or NCT#

NCT04146571

Status

not recruiting iconNOT RECRUITING

Purpose

This is an open-label, multicenter, intermediate-sized expanded access treatment protocol to the existing IND 111,695 for ensartinib (X-396). The treatment plan is designed to provide ensartinib to participants with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).

Official Title

Expanded Access Intermediate-Size Patient Population Protocol

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Heather Wakelee
Heather Wakelee
Medical oncologist, Thoracic specialist
Winston Chen and Phyllis Huang Professor

Contact us to find out if this trial is right for you.

Contact

Danielle Pancirer
650-723-0186

View on ClinicalTrials.gov